Mucopolysaccharidosis Type I Clinical Trial and Pipeline Analysis 2026: Insights into Mechanism of Action (MOA), Route of Administration (ROA), Clinical Trial Progress, and Key Companies by DelveInsight

According to DelveInsight's evaluation, the global pipeline for Mucopolysaccharidosis Type I includes over 8 leading companies actively engaged in the development of more than 8 therapeutic candidates. The analysis highlights clinical trials, therapies, mechanisms of action, routes of administration, and recent developments.

The report titled "Mucopolysaccharidosis Type I Pipeline Insight, 2026" by DelveInsight provides detailed insights into the current clinical development landscape and future growth opportunities within the Mucopolysaccharidosis Type I market.

This pipeline report offers an extensive commercial and clinical evaluation of drug candidates, ranging from preclinical stages to approved therapies. It further includes comprehensive details such as drug mechanisms of action, clinical trial progress, NDA approvals (if applicable), and product development activities, including technologies, partnerships, mergers and acquisitions, funding, regulatory designations, and other relevant updates.

Request for free sample report now: https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key highlights from the Mucopolysaccharidosis Type I Pipeline Report:
• Mucopolysaccharidosis Type I Companies worldwide are consistently working on innovative treatment approaches for Mucopolysaccharidosis Type I, achieving notable progress over time.
• Key players involved in developing therapies for Mucopolysaccharidosis Type I include BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, among others.
• Promising therapies under various stages of clinical development include ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, ISP-001, JWK-008 Chengdu, SIG 005, Pentosan Polysulphate, JNS102, and others, which are expected to significantly influence the market in the coming years.
• In December 2025, while awaiting an FDA decision expected in April for its Hunter syndrome therapy, Denali Therapeutics secured a financing deal worth $275 million with Royalty Pharma. This funding aims to support the potential commercialization of tividenofusp alfa and further strengthen its neurodegenerative pipeline. The agreement followed a three-month delay in the therapy's PDUFA date due to updated clinical pharmacology data submission. The therapy had earlier received FDA priority review in July 2025 based on Phase I/II trial results. As per the agreement, Royalty Pharma will provide an upfront $200 million upon accelerated FDA approval, along with an additional $75 million contingent on EMA approval by 2029.
• In June 2025, the European Commission granted orphan drug designation (ODD) to JR-446, an investigational therapy developed by Medipal and JCR Pharmaceuticals, for treating mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B).

Mucopolysaccharidosis Type I Overview
Mucopolysaccharidosis Type I (MPS I), also referred to as Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome, is a rare inherited disorder classified under mucopolysaccharidoses. These conditions arise due to the body's inability to effectively break down glycosaminoglycans (GAGs), resulting in their accumulation across tissues and organs.

Access the Sample Report: https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Mucopolysaccharidosis Type I Drugs in Different Clinical Phases
• ALDURAZYME (laronidase): BioMarin Pharmaceutical/Sanofi
• OTL-203: Orchard Therapeutics/Kyowa Kirin
• Lepunafusp alfa (JR-171): JCR Pharmaceuticals
• RGX-111: REGENXBIO/Nippon Shinyaku
• ISP-001: Immusoft
• JWK-008 Chengdu: Genevector Biotechnology
• RNA base-editing oligonucleotide program: EdiGene Inc.
• SIG 005: Sigilon Therapeutics
• Pentosan Polysulphate: Paradigm Biopharma
• JNS102: Jupiter Neurosciences

Mucopolysaccharidosis Type I Route of Administration (ROA)
The report evaluates pipeline drugs based on various administration routes, including:
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Mucopolysaccharidosis Type I Molecule Type Classification
Pipeline products are categorized based on molecule types such as:
• Oligonucleotides
• Peptides
• Small molecules

Mucopolysaccharidosis Type I Pipeline Therapeutics Assessment
• Assessment by product type
• Segmentation by stage and product type
• Evaluation by route of administration
• Stage-wise segmentation based on ROA
• Analysis by molecule type
• Stage-wise classification by molecule type

DelveInsight's report covers more than 8 therapies across different development phases, including:
• Phase III (late-stage) candidates
• Phase II (mid-stage) therapies
• Phase I (early-stage) products
• Preclinical and discovery-stage assets
• Discontinued or inactive programs

Download the full pipeline report:
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Mucopolysaccharidosis Type I Companies in the Market
Major organizations involved in MPS I therapeutic development include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Ultragenyx Pharmaceutical, Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals, RegenxBio, Sangamo Therapeutics, Bioasis Technologies, Paradigm Biopharmaceuticals, and others.

Mucopolysaccharidosis Type I Pipeline Analysis Insights
• The Mucopolysaccharidosis Type I market report provides a comprehensive overview of companies developing MPS I therapies along with their respective pipeline portfolios.
• It categorizes therapeutic candidates based on early, mid, and late stages of development.
• Key Mucopolysaccharidosis Type I companies are engaged in developing targeted therapies, including both active and inactive projects.
• Mucopolysaccharidosis Type I Drug candidates are analyzed based on development stage, route of administration, target receptors, monotherapy or combination therapy approaches, mechanisms of action, and molecular types.
• The Mucopolysaccharidosis Type I market report also offers detailed insights into collaborations, licensing agreements, and funding activities supporting pipeline advancement.
The study is compiled using data sourced from proprietary databases, company and academic websites, clinical trial registries, conferences, SEC filings, investor presentations, and industry-specific third-party resources.

Mucopolysaccharidosis Type I Market Drivers
• Rising prevalence of Mucopolysaccharidosis Type I and improved understanding of disease pathogenesis are key factors driving market growth.

Mucopolysaccharidosis Type I Market Challenges
• Limited awareness regarding symptoms and difficulties in predicting disease severity during newborn screening remain significant barriers to market expansion.

Mucopolysaccharidosis Type I Mrket Report Scope
• Coverage: Global
• Key Companies: BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, and others
• Key Therapies: ALDURAZYME, OTL-203, Lepunafusp alfa, RGX-111, ISP-001, and more
• Therapeutic Coverage: Marketed and emerging therapies
• Market Dynamics: Drivers and barriers shaping the MPS I market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.